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Abstract 
The Impact of Clinical Pharmacy Services in a Veterans Affairs Hospital 
Emergency Department 
Problem: The Michael E. DeBakey Veterans Affairs Medical Center is a large tertiary 
care teaching hospital with a busy emergency department. Currently there are no 
pharmacy services provided in the emergency department, which is similar to national 
trends.  
Methods: A one-month pilot was arranged to place a clinical pharmacist in the 
emergency department during the day shift. Pharmacist interventions and activities were 
chronicled and translated into financial savings for the hospital. In addition to 
intervention tracking the pharmacist focused on Adverse Drug Event reporting and 
discharge counseling. Review of the number of Adverse Drug Event reports during the 
month was compared to the months surrounding the pilot period. Readmission rates for 
patients seen for Chronic Obstructive Pulmonary Disease were also compared to the 
months surrounding the pilot. Comparisons were made using Chi Square analysis. 
Results: The pharmacist made a total of 68 quantifiable interventions for a total cost 
avoidance of $97,953.90. In addition, the pharmacist completed 207 medication 
reconciliations, 29 discharge counseling sessions, and a small number of other 
interventions. There were a total of 10 Adverse Drug Events reported during the pilot 
period, which demonstrated a significant increase in reporting during the pilot (p < 0.01). 
There was no difference seen in readmission rates. 
Conclusions: Addition of a clinical pharmacist to the emergency department resulted in 
significant cost savings for the hospital. In addition, there was a significant increase in 
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Adverse Drug Event reporting, which would more accurately reflect the number of 
medication events in the hospital. 
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Chapter 1 
Introduction 
Medication Safety 
Medication errors are a known problem in healthcare. The Institute of Medicine 
released a report to document the scope of this problem in the American healthcare 
system. To Err is Human changed the landscape of medication safety, and helped bring 
this large-scale problem into the public eye. This report also provided recommendations 
to help improve the medication use system (Kohn et al., 1999).  The Institute of Medicine 
followed up with a second publication intended to help shape the goals of the 21
st
 century 
healthcare system. Crossing the Quality Chasm provided further recommendations for 
ideals that could help improve the medication use system. Among the recommendations 
there was advice to improve evidence based care for patients (IOM, 2001).  These two 
landmark reports created the awareness of the problem, but progress towards a safe 
medication system is still lacking. Many known improvements to the system have not 
been widely adopted after successful demonstration in individual hospitals or systems 
(Leape and Berwick, 2005).  
Within the Veterans Affairs (VA) health system, medication safety is of high 
importance. The VA Adverse Drug Event Reporting System (VA ADERS) is designed to 
allow facilities to record adverse reactions of patients to medications. The system 
electronically records all information related to the event and determines the likelihood of 
the event resulting from the use of a specific medication. The system is designed to 
automatically report the information to the Food and Drug Administration when any 
reactions are severe or occur for drugs that are newly approved. VA policy defines an 
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Adverse Drug Event (ADE) as an injury resulting from the use of a drug, including harm 
caused by the drug as a result of adverse drug reactions, drug-drug interactions, product 
quality problems or drug overdoses (whether accidental or intentional). This definition 
includes Adverse Drug Reactions, which are defined as a response to a drug which is 
noxious and unintended and which occurs at doses normally used in man for prophylaxis, 
diagnosis, or therapy of disease or for the modification of physiologic function (VHA 
2008). ADE reporting can be accomplished by any staff member of the VA, but is often 
catalogued by either the provider or the pharmacist. Involvement of a pharmacist in the 
emergency department has been shown to increase the reporting of adverse drug events in 
other healthcare systems (Weant et al., 2010). 
 The pharmacy department is responsible for effective medication distribution 
within the hospital. The Joint Commission Standards require all orders to be reviewed by 
a pharmacist prior to administration unless they are under the direct supervision of the 
physician from ordering to preparing and administering the medication (MM.05.01.01) 
(TJC, 2012). This measure is intended to improve patient safety and reduce medication 
errors. Increased involvement of clinical pharmacists has been shown to improve the 
medication delivery system. System changes in pharmacy departments have already 
shown improvement in patient safety through the reduction of medication errors. 
Programs related to computerized physician order entry, bar coded medication 
administration, and smart pump technologies have demonstrated improved patient safety 
(Roberts et al., 2010; Marini and Hasman, 2009; Trbovich et al., 2010). In addition to 
technological changes for patient safety, the involvement of a clinical pharmacist has 
been shown to improve patient safety (Kaboli et al., 2006).  
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Emergency Department 
 The emergency department serves as an entry point to most hospitals and provides 
the first opportunity for the facility to provide quality care. However, only 28.6% of 
hospitals currently have a pharmacist assigned to cover the emergency department 
(Pedersen et al., 2010). The rates of medication errors in emergency departments have 
been reported at 26.4% (Liu et al., 2009) to 30% in the absence of a pharmacist (Ernst et 
al., 2011). These numbers indicate that while there are many errors that take place in the 
emergency department, there are few hospitals that have been proactive to place a 
pharmacist in the emergency department to reduce these error rates.  
The Veterans Affairs Hospital in San Diego implemented a 24-hour emergency 
department pharmacy program in 2007. The San Diego VA is a 238-bed teaching 
hospital, and their ED sees approximately 32,000 patients per year. Their program 
involved five pharmacists providing 24-hour coverage to the ED, and measured 
interventions for the first six months of the program. The pharmacists documented 7,598 
medication reconciliation encounters and 9,568 clinical interventions during the study 
period. The cost avoidance from these interventions was calculated to be $845,592 for the 
six-month trial period, and extrapolated to one-year results in $1,691,185 of cost 
avoidance. An employee satisfaction survey was also included as part of the study, and 
revealed that 90% of ED staff was strongly satisfied with the ED pharmacy program 
(Alderidge et al., 2009). 
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Readmission Rates 
 While controversial, hospital readmission rates have been used as a proxy 
measure to estimate the quality of care that patient's receive (Joynt and Jha, 2012). 
Pharmacist interventions have been demonstrated to show changes in the cost and 
appropriateness of hospital care, but have not shown any differences in readmission rates 
(Walker et al., 2009; Koehler et al., 2009).  Generally, pharmacist interventions in this 
area revolve around patient counseling and medication reconciliation. Further 
information is needed to determine the most beneficial aspects of pharmacist care 
affecting readmission rates. 
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Purpose 
 
While pharmacy services in the emergency department have been evaluated in many 
settings, the methods for creating a new program have not been explored. The purpose of 
this project is to pilot clinical pharmacy services in the emergency department, and 
analyze the impact of these services on the hospital. 
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Specific Aims 
 
To determine the financial viability of a clinical pharmacist emergency department 
program through evaluation of daily activity reports.  
1.  Daily activity logs of pharmacist activities were used to convert interventions 
into financial cost savings for the hospital. 
2. Impact on adverse medication event reporting was used to determine the 
impact of a pharmacist on safety measures in the ED. 
3. Impact of pharmacist counseling on readmission rates was determined through 
30 day readmission rates for patients seen for COPD in the emergency 
department. 
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Chapter 2 
Methods 
 
The Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) is a 
large teaching hospital in Houston, Texas. The facility contains 359 acute care medicine 
beds, 40 spinal cord unit beds, and 141 long-term care nursing home beds. This is one of 
the largest VA hospitals in the country. The current workload volume for the emergency 
department has been steadily increasing over the past few years as the number of eligible 
patients has continued to increase. The volume of patient encounters has increased from 
approximately 1700 encounters per month in the fall of 2000 to approximately 3100 
encounters in the summer of 2011. This doubling of workload has placed stress on the 
emergency department staff, and increased the need for additional help in the department. 
 Setting up the clinical pharmacist pilot in the emergency department involved 
coordination between multiple departments. The pharmacy department analyzed the staff 
resources available to conduct such a pilot, and the emergency department staff provided 
space for inclusion of a pharmacist in the workflow. In order to maximize the benefits of 
pharmacist participation in the ED, the pharmacy department reviewed potential 
employees to include in the pilot. One internal medicine clinical pharmacist was found 
that was qualified, capable, and desired involvement in the project. She was selected to 
take part in the ED pilot and provided pharmacy services during her regularly scheduled 
daytime shift during the week. At this time due to staffing issues in other areas, the VA 
was unable to provide further coverage of the ED during the pilot. Therefore, we had a 
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pharmacist in the ED for forty hours per week for the entire month. Interactions with the 
ED staff helped to shape the functions that the pharmacist provided during the pilot.  
 During discussions with the ED staff, we determined potential areas of impact for 
the pharmacist to include medication reconciliation, increased adverse event reporting, 
recommending alterations to therapy regimens, and drug information education. The 
pharmacist was involved in the determination of potential roles in the ED as well. These 
areas were specifically targeted as areas for pharmacist impact, but other areas of 
involvement were expected once the pharmacist was incorporated into the work flow.  
 Clinical pharmacy services were provided to the emergency department from 7:30 
AM to 4:00 PM five days per week from Monday, November 28, 2011 through Friday, 
December 30, 2011. The pharmacist shared space in the emergency department nursing 
station in order to remain visible to all staff in the area. All providers share office space 
within the same nursing station to allow for informal consultation and discussion of 
patients. The pharmacist took a proactive role in patient care by performing medication 
reconciliation on newly admitted patients prior to the physician examination and 
conveyed important findings as needed. Through these interactions, the providers gained 
greater trust in the pharmacist and used her for drug information questions.  
The current intervention tracking system for VA pharmacists is an online web-
based recording system. This system was viewed as impractical based on the 
requirements for internet access to record all interventions, time to connect to the server, 
and limitations on the type of interventions recorded. Instead a small pocket card was 
created to record only the essential elements of the interventions such as action 
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performed, time spent, and patient reference in case the pharmacist needed to review the 
patient further. The pharmacist recorded a short description of each intervention or 
activity on the card that provided enough information to determine what was done. These 
interventions were categorized based on previous research conducted at another VA 
facility (Lee et al., 2002). Once categorized all interventions were translated into 
financial impact using the median inpatient financial impact determined by Lee and 
colleagues. In their previous research, they determined the financial cost avoidance for 
the VA based on pharmacist interventions. Factors included in their cost analysis 
included the cost of medications, changes in the length of stay, cost for treatment of 
adverse events, and salary for healthcare providers. In their study, a physician and 
pharmacist both independently reviewed interventions to determine a range for the cost 
avoidance of each type of intervention. The average cost was taken between these two 
reviewers and determined to be the estimated cost avoidance of each intervention type 
(Lee at al., 2002). 
After categorizing each pharmacist intervention, the median cost avoidance was 
multiplied by the number of interventions within each category. Next the cost avoidance 
figures were adjusted to current values to account for inflationary impacts on cost. The 
Medical Purchase portion of the Consumer Price Index was used to adjust the figures 
from the 2002 dollars from the previously published study to 2011 dollars at the time of 
the pilot. Adjustment is made through dividing the 2002 cost figure by the 2002 Medical 
Purchase portion cost and then multiplying by the 2011 Medical Purchase portion cost. 
This provides an adjustment based on the ratio of the different costs. The Medical 
Purchase portion was used for adjustment since it provides a specific measure for medical 
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care. The index factors medication costs, provider costs, and hospital costs each year as 
part of the calculation of the annual Consumer Price Index by the Bureau of Labor and 
Statistics (BLS, 2002; BLS, 2011). The Medical Purchase portion cost was used instead 
of the overall Consumer Price Index for inflation because medical costs have been 
increasing at a rate higher than inflation in the United States (Mitka, 2009).  
Reported interventions were also analyzed for severity. In order to assess severity 
of the interventions, a scale was used based on the potential for harm if the intervention 
was not made. To determine intervention severity, a previously reported ADE severity 
scoring criteria was applied (Appendix B) (Morimoto et al., 2004). One pharmacist 
reviewed each specific intervention and determined the patient harm that may have 
resulted if the intervention was not followed. Interventions that were categorized as 
serious or life threatening were then separated out for additional cost avoidance 
calculations to determine the impact of the more serious interventions. 
 During the pilot, the pharmacist was instructed to ensure accurate reporting of 
adverse Drug events according the VA policy. The pharmacist recorded ADEs from the 
ED and placed the report in the VA ADERS system as time permitted. Classification of 
ADEs follows the VA definitions of ADE as “an injury resulting from the use of a drug. 
For the purposes of this Directive, this definition includes harm caused by the drug as a 
result of adverse drug reactions, drug-drug interactions, product quality problems or drug 
overdoses (whether accidental or intentional)” while an adverse drug reaction is defined 
as “a response to a drug which is noxious and unintended and which occurs at doses 
normally used in man for prophylaxis, diagnosis, or therapy of disease or for the 
modification of physiologic function. (VHA, 2008)” These definitions were utilized for 
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all ADE reporting from the pilot performed in the ED to ensure equal comparison to any 
reports filed during the comparator months when a pharmacist was not present in the ED. 
Information included in the reporting is the date of event, type of event, and potential 
preventability based on questions related to monitoring and appropriateness of therapy. 
To determine the pharmacist impact on ADE reporting, the number of reports filed during 
the month prior to the pilot and the month following the pilot were compared to the pilot 
month. Data was taken from the VA ADERS reporting system, which collects the reports 
from all sources and maintains a database. Events were quantified along with the number 
of patient encounters within the ED to determine an ADE rate per encounter. 
Comparisons of ADE reports were made using Chi Square Fisher exact analysis (SAS 
9.2, Cary NC).  
 Readmission rates for patients seen for Chronic Obstructive Pulmonary Disease 
(COPD) in the ED were reviewed. A list of patients with an encounter with COPD as a 
diagnosis in the ED was created for each month in the evaluation period. Patients were 
excluded from the analysis if they were admitted to the hospital directly from the ED 
because alternate education and interventions take place at hospital discharge. Any 
patient seen and discharged directly from the ED was included in the analysis irrespective 
of the time of day they were seen in the ED. If a patient experienced multiple admissions 
during the study period, only the first encounter was used for analysis. Patient charts were 
then reviewed to determine the 30 day all cause readmission rate for patients seen in the 
ED. Readmission was defined as return to the ED or admission to the hospital for any 
cause during the first 30 days following the encounter in the ED. COPD specific 
readmission rates were also determined through review of secondary admission data. The 
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readmissions were compared using the number of readmissions per patients seen for 
COPD each month. Comparison of readmission rates was made using Chi Square 
analysis. 
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Chapter 3 
Results 
 
Financial Analysis  
 During the course of the five-week pilot study, the pharmacist was able to 
perform 207 medication reconciliations, and provided discharge counseling for 29 total 
patients. These activities were not translated into financial benefit, but provided 
additional services to patients and staff in the ED. The total number of interventions 
recorded by the pharmacist and their categorization were catalogued and demonstrated a 
total of 68 interventions for financial analysis (Table 1). This provided a total of $69,894 
of cost avoidance from pharmacist interventions. Adjustment of financial data was made 
to reflect 2011 dollar values by adjusting for inflation the numbers based on the 2002 
data source. After adjustment for inflation the cost avoidance of pharmacist interventions 
was calculated to be $97,953.90. Expected savings from a pharmacist in the ED would be 
$1,018,720.52 per year.  
Table 1: Financial Impact of Pharmacist Interventions 
Type of intervention Number of 
interventions 
Cost in 2002 
Dollars 
($) 
Cost in 2011 
Dollars 
($) 
Drug Interaction 5 8,235 11,541.05 
Prevent/Manage Drug 
Allergy 
1 1,375 1,927.01 
Adjust dosage or frequency 28 33,264 46,618.28 
Untreated diagnosis 18 19,908 27,900.34 
Drug not indicated 8 5,792 8,117.28 
Duplication of therapy 8 1320 1,849.93 
Total Interventions 68 69,894 97,953.90 
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 The financial impact of the pharmacist interventions was also determined based 
on the severity of the intervention. When interventions were categorized based on the 
potential for patient harm, a total of thirty-four interventions were deemed serious or life 
threatening (Table 2). When only these interventions were used for cost avoidance the 
financial impact is reduced to a total of $56,012.30 for the intervention period, and 
$582,527.87 extrapolated over the full year (Table 3). 
Table 2: Severity Scoring for all Pharmacist Interventions 
 
Table 3: Cost Avoidance from Serious or Life Threatening Interventions 
Type of intervention Number of 
interventions 
Cost in 2002 
Dollars 
($) 
Cost in 2011 
Dollars 
($) 
Drug Interaction 2 3,294 4,616.42 
Prevent/Manage Drug 
Allergy 
1 1,375 1,927.01 
Adjust dosage or 
frequency 
17 20,196 28,303.96 
Untreated diagnosis 13 1,4378 20,150.24 
Drug not indicated 1 724 1,014.66 
Duplication of Therapy 0 0 0 
Total Interventions 34 39,967 56,012.30 
 
In addition to the interventions used to calculate financial impact, the pharmacist 
was able to provide other services that were not categorized (Table 4). These services are 
valuable services to the hospital, but could not be quantified in a similar manner.  
Severity Level Number of interventions 
Fatal 0 
Life Threatening 7 
Serious 29 
Significant 18 
Minor 14 
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Table 4: Other Activities of the Pharmacist in the Emergency Department 
Additional Duty Number of Occurrences 
Medication Reconciliation 207 
Discharge Counseling 29 
Order/Interpret labs 5 
Complete allergy assessment 2 
Update order sets 4 
Education/Drug information  8 
Added med to ward stock based on usage 1 
 
Adverse Drug Event Reporting Analysis 
 Previous reporting of ADEs has varied greatly in the MEDVAMC ED. Over the 
past three years, the number of ADEs reported through VAADERS has ranged from 0 to 
21 per quarter. There were 16 total ADEs reported during the study period in the 
emergency department. The month prior to the pilot there were a total of 6 ADEs 
reported and in the month following the pilot there were 0 ADEs reported. During the 
pilot period a total of 10 ADEs were reported in the ED (Table 5). The change in the 
number of ADEs reported was found to be statistically significant (p < 0.01). 
Table 5: Adverse Drug Events reported in the Emergency Department 
Month ADEs reported Total ED encounters 
November 6 3,138 
December 10 2,962 
January 0 3,339 
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Readmission Rates of COPD Patients 
 Review of the 30-day readmission rates for patients seen for COPD in the ED 
were reviewed. In the month prior to the pilot there were a total of 52 patients seen for 
COPD in the ED. The 30-day all cause readmission rate was 21.2% (11 patients). During 
the study period a total of 36 patients were seen for COPD, and there was a resultant 
readmission rate of 25% (9 patients). The month following the pilot study had 46 patient 
encounters for COPD, and showed a readmission rate of 39.1% (18 patients) (Table 6). 
Further review of the readmitted patients revealed no difference in the rate of readmission 
specific to COPD, and showed an increasing trend over the three-month period. The 
change in readmission rates was not statistically significant. 
Table 6: Readmission Rates for Patients Seen for COPD 
Month COPD patient 
encounters 
30 day Readmission rate 
(%) 
30 day COPD specific 
Readmission rate (%) 
November 53 18.9 15.4 
December 39 33.3 16.7 
January 44 38.6 26.1 
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Chapter 4 
Discussion 
 The results of this study are valuable for the host institution to know the specific 
impact that could be expected from having clinical pharmacist coverage of the ED. The 
financial results are overwhelmingly in favor of having a clinical pharmacist cover the 
ED, because the return on investment would be approximately $7.84 for each $1 spent for 
the clinical pharmacist using total intervention savings and $4.48 for each $1 spent using 
only serious interventions. This is based on the yearly-extrapolated cost avoidance and 
the estimated cost of one clinical pharmacist's salary and benefits (Estimated at $130,000 
per year). The findings from this study are in line with the expected cost savings seen 
from other studies of clinical pharmacist services that have shown to provide a return on 
investment of $4.81 for every $1 spent (Perez et al., 2008).    
 Compared to other previous studies looking at pharmacist financial impact in the 
ED, this study was within the range of accepted values. Cost avoidance figures have been 
provided with multiple retrospective studies. The range for cost avoidance has been 
shown to be between $100,000 per year to upwards of $3,000,000 per year (Levy, 1993; 
Fairbanks et al., 2004; Ling et al., 2005; Lada et al., 2007; Aldridge et al., 2009). The 
capacity of the ED in these studies has generally been around 80,000 to 100,000 patient 
visits per year, but in the San Diego VA study the volume of patient visits was 
approximately 30,000 per year. When healthcare inflation is added to the previously 
published studies, this study provided a mid range value for cost avoidance for clinical 
pharmacist coverage of the ED.  
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 The pharmacist was able to provide patient interventions through performing 
medication reconciliation, answering drug information questions, and helping develop 
treatment plans. Due to the nature of the ED in our facility, the pharmacist was required 
to be proactive to get involved with patient care. The easiest way for the pharmacist to 
gain involvement was through medication reconciliation. The pharmacist was able to 
perform 207 medication reconciliations, which lead to an average of 0.32 interventions 
per medication reconciliation. With the current organization of our emergency 
department, this would be the most valuable function of the pharmacist. However, if the 
VA's computerized physician order entry system and bar coded medication 
administration system were extended to the ED the pharmacist could perform prospective 
medication order review. This would likely lead to increased interventions and work for 
the pharmacist within the ED. From this project the most important role of the pharmacist 
would be deemed to be medication reconciliation, and prospective medication order 
review would only enhance their activities. 
In addition to the financial benefits to the hospital, the pilot demonstrated an 
increased number of ADEs reported. This indicates that ADEs are currently 
underreported in the ED, because the pharmacist was only reporting observed events. 
This change represents an almost doubling of ADEs reported during the pilot period, 
which was followed by a complete lack of any reports the following month. This data 
shows a significant increase in reporting with a clinical pharmacist present in the ED. 
Without accurate reporting of ADEs it is impossible for the hospital to know what the 
best way to improve patient medication related care. The number reported without 
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clinical pharmacist involvement is an underestimate of the actual number of ADEs that 
occur.  
The readmission data indicate that clinical pharmacist involvement in the ED has 
no effect for patients with COPD. This result was not surprising based on the small 
amount of time the pharmacist was able to spend with each unique patient. In addition, 
the analysis did not exclude patients seen in the ED when the pharmacist was not 
working, which indicates that many of the patients cared for during the pilot period had 
no pharmacist care. The readmission numbers for return visited related to COPD 
increased in the January period of the study over the previous two months. This increase 
was not significant but represented a substantial change in the percent of patients 
readmitted specifically for COPD. This could be related to chance due to the small 
sample size of patients seen in all three months, and could also be related to the time of 
year. January is a colder month and traditionally is part of the cold and flu season in the 
area. While the numbers are not significant there is the potential for a targeted counseling 
program to show benefit in COPD patients. This would need to be tested with further 
studies that incorporate a randomized design and include many more patients. 
While this study provides evidence for the value of clinical pharmacy services in 
the ED, there is not explicit proof that the pharmacist interventions would not have 
occurred without them. In order to determine the complete impact of the pharmacist in 
the ED, future studies would be needed. A randomized trial would be warranted to 
determine the exact financial impact on the facility. In order to create this comparison, 
patients would be randomized at entry to the ED to a pharmacist followed team or a 
traditional coverage team, and comparison of patient costs would then be analyzed for not 
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only the time spent in the ED but also the remainder of the hospital course. This type of 
study would require vast resources and may be unfeasible for any single institution, but 
would provide a definitive answer to the financial impact of clinical pharmacy services in 
the ED.  
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Limitations 
 While this pilot study has provided great data for the justification of clinical 
pharmacy services in the ED, there are many limitations to the pilot. First, the month the 
study was conducted was in December 2011. The time of the study could lead to 
increased potential interventions for the pharmacist due to alternate medical staff 
coverage during the holiday season. Many physicians and nurses take additional vacation 
time during this time of year.  
 Conversely the number of interventions was limited for the pharmacist because 
there is not prospective medication order review by the pharmacist in the MEDVAMC 
ED. The results discovered from this study are likely a dramatic underestimation of cost 
avoidance. The clinical pharmacist was forced to be proactive to interact with physicians 
in recommending medication changes. Having prospective review of all orders would 
lead to greater opportunity to intervene with allergy avoidance, dosage adjustment, and 
drug interactions. The pharmacy could not provide this service at the time of the pilot due 
to limitations in the computer software. If this were to be pursued in the future there 
would need to be 24-hour coverage of the ED to accommodate the increase in workload 
for the pharmacy department. 
 The clinical pharmacist work schedule was during the day shift for the hospital. 
Due to scheduling conflicts, we were unable to alter that schedule during the pilot. It is 
known that the greatest number of ED encounters occur during the day and evening 
shifts. Thus the ED was getting busier as the pharmacist shift was ending. This indicates 
that the shift selected was not the ideal shift to maximize pharmacist interventions. If the 
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pilot was conducted during an alternate shift that covered the early afternoon through 
early evening times, the number of interventions would be expected to increase.  
 The number of patients the pharmacist was able to see during the pilot period 
limits the review of readmission rates. Many patients way have been in the ED during 
other portions of the day and had no interaction with the pharmacist. Thus the 
readmission rates may not accurately reflect the rates from patients seen during 
pharmacist coverage hours. This makes a difference more difficult to demonstrate during 
the pilot period. 
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Conclusions 
 Addition of a clinical pharmacist to the ED demonstrated significant cost 
avoidance and increased ADE reporting. There was no difference in readmission rates of 
COPD patients. The addition of a full time clinical pharmacist to cover the ED would 
provide positive financial returns for the hospital. 
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Appendix A 
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Appendix B 
Severity Examples 
Fatal Patient died due to the incident 
Life Threatening Patient transferred to ICU 
Respiratory failure requiring intubation 
Mental status change: patient falls and gets intracranial 
hemorrhage 
Tongue swelling/anaphylactic shock 
Serious Gastrointestinal bleed 
Altered Mental Status: excessive sedation 
Increased Creatinine  
Decreased blood pressure: patient feels lightheaded 
Allergic reaction: shaking chills/fever 
Additional visit to clinic or treatment with additional 
medication 
Significant Rash 
Diarrhea due to antibiotics 
Thrombocytopenia due to histamine type 2 antagonist 
Nausea resulting from oral potassium 
Nausea and Vomiting from erythromycin 
Any significant event identified by the patient but not requiring 
a change in therapy 
Taken from Morimoto et al. 
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